ASLAN Pharmaceuticals Limited

0.4872+0.0269+5.84%Vol 123.31K1Y Perf -86.96%
Jun 24th, 2022 15:59 DELAYED
BID0.4700 ASK0.5191
Open0.4880 Previous Close0.4603
Pre-Market- After-Market0.51
 - -  0.02 4.45%
Target Price
6.33 
Analyst Rating
Strong Buy 1.00
Potential %
1.20K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     49.47
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.81 
Earnings Rating
Strong Sell
Market Cap33.98M 
Earnings Date
5th Aug 2022
Alpha-0.04 Standard Deviation0.33
Beta2.36 

Today's Price Range

0.47690.5200

52W Range

0.35553.81

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
25.89%
1 Month
21.80%
3 Months
-43.53%
6 Months
-60.71%
1 Year
-86.96%
3 Years
-86.00%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ASLN0.48720.02695.84
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
9.30
9.60
0.45
0.81
-13.80
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
0.00
-168.60
-156.60
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.17-0.19-11.76
Q04 2021-0.15-0.16-6.67
Q03 2021-0.12-0.120.00
Q02 2021-0.11-0.0827.27
Q01 2021-0.11-0.13-18.18
Q04 2020--0.15-
Q03 2020-0.10-0.0280.00
Q02 2020-0.10-0.100.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.20-25.00Negative
9/2022 QR-0.20-25.00Negative
12/2022 FY-0.66-20.00Negative
12/2023 FY-0.89-78.00Negative
Next Report Date5th Aug 2022
Estimated EPS Next Report-0.20
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume123.31K
Shares Outstanding69.74K
Shares Float69.74M
Trades Count422
Dollar Volume60.25K
Avg. Volume353.06K
Avg. Weekly Volume399.02K
Avg. Monthly Volume408.35K
Avg. Quarterly Volume251.80K

ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) stock closed at 0.4872 per share at the end of the most recent trading day (a 5.84% change compared to the prior day closing price) with a volume of 123.31K shares and market capitalization of 33.98M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. ASLAN Pharmaceuticals Limited CEO is Carl Firth.

The one-year performance of ASLAN Pharmaceuticals Limited stock is -86.96%, while year-to-date (YTD) performance is -56.5%. ASLN stock has a five-year performance of %. Its 52-week range is between 0.3555 and 3.81, which gives ASLN stock a 52-week price range ratio of 3.81%

ASLAN Pharmaceuticals Limited currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 0.60, a price-to-sale (PS) ratio of 23.43, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.06%, a ROC of -39.27% and a ROE of -61.70%. The company’s profit margin is -%, its EBITDA margin is -156.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ASLAN Pharmaceuticals Limited, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. ASLAN Pharmaceuticals Limited’s next earnings report date is 05th Aug 2022.

The consensus rating of Wall Street analysts for ASLAN Pharmaceuticals Limited is Strong Buy (1), with a target price of $6.33, which is +1 199.26% compared to the current price. The earnings rating for ASLAN Pharmaceuticals Limited stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ASLAN Pharmaceuticals Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ASLAN Pharmaceuticals Limited has a Neutral technical analysis rating based on Technical Indicators (ADX : 45.43, ATR14 : 0.06, CCI20 : 182.98, Chaikin Money Flow : -0.53, MACD : -0.01, Money Flow Index : 76.13, ROC : 35.33, RSI : 59.35, STOCH (14,3) : 67.71, STOCH RSI : 1.00, UO : 25.08, Williams %R : -32.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ASLAN Pharmaceuticals Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology and oncology-focused biopharmaceutical company. It is engaged in developing treatments to transform the lives of patients. The company has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.

CEO: Carl Firth

Telephone: +65 62224235

Address: 83 Clemenceau Avenue, Singapore 239920, , SG

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

70%30%

Bearish Bullish

62%38%

Bearish Bullish

62%38%

TipRanks News for ASLN

News

Stocktwits